[go: up one dir, main page]

WO2005048944A3 - Activatable photodynamic therapy agents - Google Patents

Activatable photodynamic therapy agents Download PDF

Info

Publication number
WO2005048944A3
WO2005048944A3 PCT/US2004/038024 US2004038024W WO2005048944A3 WO 2005048944 A3 WO2005048944 A3 WO 2005048944A3 US 2004038024 W US2004038024 W US 2004038024W WO 2005048944 A3 WO2005048944 A3 WO 2005048944A3
Authority
WO
WIPO (PCT)
Prior art keywords
photodynamic therapy
therapy agents
activatable
methods
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/038024
Other languages
French (fr)
Other versions
WO2005048944A2 (en
Inventor
Gang Zheng
Jerry D Glickson
Britton Chance
Edward James Delikatny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of WO2005048944A2 publication Critical patent/WO2005048944A2/en
Publication of WO2005048944A3 publication Critical patent/WO2005048944A3/en
Anticipated expiration legal-status Critical
Priority to US11/383,487 priority Critical patent/US8133482B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the field of conjugates comprising a first substrate which is attached to a least one photosensitizer and at least ont first quencher, and methods for their use. More particularly, the present invention relates to photodynamic therapy agents. The invention further relates to methods for decontaminating blood and methods for treating cancer or viral infection in a subject using the conjugates of the present invention.
PCT/US2004/038024 2003-11-14 2004-11-15 Activatable photodynamic therapy agents Ceased WO2005048944A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/383,487 US8133482B2 (en) 2003-11-14 2006-05-15 Activatable photodynamic therapy agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51979403P 2003-11-14 2003-11-14
US60/519,794 2003-11-14
US55850104P 2004-04-01 2004-04-01
US60/558,501 2004-04-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/383,487 Continuation-In-Part US8133482B2 (en) 2003-11-14 2006-05-15 Activatable photodynamic therapy agents

Publications (2)

Publication Number Publication Date
WO2005048944A2 WO2005048944A2 (en) 2005-06-02
WO2005048944A3 true WO2005048944A3 (en) 2006-05-04

Family

ID=34623104

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038024 Ceased WO2005048944A2 (en) 2003-11-14 2004-11-15 Activatable photodynamic therapy agents

Country Status (1)

Country Link
WO (1) WO2005048944A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125829B2 (en) 2012-08-17 2015-09-08 Hallstar Innovations Corp. Method of photostabilizing UV absorbers, particularly dibenzyolmethane derivatives, e.g., Avobenzone, with cyano-containing fused tricyclic compounds
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039994A2 (en) * 2006-09-28 2008-04-03 The Trustees Of The University Of Pennsylvania Targeted photodynamic therapy agent
WO2009111439A2 (en) 2008-03-04 2009-09-11 The Trustees Of The University Of Pennsylvania In vivo detection of phospholipase activation
EP2717857B1 (en) * 2011-06-06 2018-07-11 University Health Network (UHN) Method for the synthesis of porphyrin-phospholipid conjugates
EP2858503B1 (en) 2012-06-04 2020-06-03 Suncor Energy Inc. Formulations containing paraffinic oil and anti-settling agent
WO2014025370A1 (en) * 2012-08-10 2014-02-13 Hallstar Innovations Corp. Tricyclic energy quencher compounds for reducing singlet oxygen generation
CA2877585C (en) 2013-03-15 2016-04-12 Suncor Energy Inc. Herbicidal compositions
WO2016157198A1 (en) * 2015-03-31 2016-10-06 Galia Blum Photodynamic quenched activity based probes and uses thereof in imaging and targeted therapy
CN105694851B (en) * 2016-03-08 2018-07-27 武汉大学 A kind of cancer target diagnosis and treatment fluorescence probe
EP3600371A4 (en) * 2017-03-21 2021-06-09 The Regents of The University of Michigan ERG-TARGETED THERAPY
US12207655B2 (en) 2019-02-15 2025-01-28 Nutrien Ag Solutions (Canada) Inc. Protoporphyrin IX derivatives and use thereof to improve the health of plants
US20230190933A1 (en) * 2020-05-12 2023-06-22 Institute Of Process Engineering, Chinese Academy Of Sciences Immunologically Active Peptide-Biliverdin Conjugate, Preparation Method Therefor and Application Thereof
CN116102741B (en) * 2023-04-10 2023-06-20 中国农业科学院农业质量标准与检测技术研究所 Magnetic nanocomposite material for removing bee venom allergens and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103751A (en) * 1998-06-22 2000-08-15 Health Research, Inc. Carotene analogs of porphyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159445A (en) * 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US6540981B2 (en) * 1997-12-04 2003-04-01 Amersham Health As Light imaging contrast agents
US6103751A (en) * 1998-06-22 2000-08-15 Health Research, Inc. Carotene analogs of porphyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATAYOSHI E.D. ET AL: "Novel Fluorogenic Substrates for Assaying Retroviral Protease by Resonance Energy Transfer", SCIENCE, vol. 247, no. 4945, 23 February 1990 (1990-02-23), pages 954 - 958, XP002056345 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145383B2 (en) 2012-08-10 2015-09-29 Hallstar Innovations Corp. Compositions, apparatus, systems, and methods for resolving electronic excited states
US9125829B2 (en) 2012-08-17 2015-09-08 Hallstar Innovations Corp. Method of photostabilizing UV absorbers, particularly dibenzyolmethane derivatives, e.g., Avobenzone, with cyano-containing fused tricyclic compounds

Also Published As

Publication number Publication date
WO2005048944A2 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
WO2005048944A3 (en) Activatable photodynamic therapy agents
DK1267897T3 (en) Treatment of congestive heart failure with pretreated autologous blood
WO2003043697A3 (en) Therapeutic light-emitting device
CR7330A (en) PROCEDURE FOR TREATING EYE NEOVASCULAR DISEASES
WO2004091531A3 (en) Methods and devices for epithelial protection during photodynamic therapy
DK1373215T3 (en) Gelanamycin derivatives suitable for the treatment of cancer
AU2001297644A1 (en) B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
WO2006076506A3 (en) Treating a diseased nail
WO2004064734A3 (en) Combination therapies for the treatment of cancer
UY27186A1 (en) PHARMACEUTICAL FORMULATION
WO2005070052A3 (en) Use of photodynamic therapy to enhance treatment with immuno-modulating agents
IL158032A (en) Metal substituted non centrosymmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostics
BRPI0418157A (en) allogeneic tumor therapy
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
WO2003049804A3 (en) Treatment of genitourinary tract disorders
BRPI0517976A (en) treatment methods
WO2001024825A3 (en) Significance of dosimetry in photodynamic therapy of injured arteries
AU2001253125A1 (en) Intracorporeal medicaments for high energy phototherapeutic treatment of disease
WO2001008704A3 (en) Dendrimer-photosensitizer complexes for medical applications
WO2003032902A3 (en) Tumor targeted photodiagnostic-phototherapeutic agents
WO2003018006A1 (en) Porphyrin-zinc oxide complex and use of the same as photosensitive medicament which exitates photodynamic action by radiation and the use thereof in targeted therapy
DK1150981T3 (en) Therapeutic necleoside compound

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase